Stem Cells for COVID-19 ARDS

Published 2020-09-16

A clinical trial led by Michael Matthay, M.D. at the University of California, San Francisco is exploring the potential of Bone Marrow derived Mesenchymal Stem Cells (MSCs) for COVID-19 pneumonia related Adult Respiratory Distress Syndrome (ARDS). In the treatment arm of the study, patients will receive two intravenous infusions of 2 million MSCs/kg. The study is anticipated to enroll 300 patients in total.